Product
Supplier
Encyclopedia
Inquiry
Home > Encyclopedia > Ranirestat

Ranirestat

pharmaceutical raw materials
Ranirestat structure

Ranirestat 

structure
  • CAS No:

    147254-64-6

  • Formula:

    C17H11BrFN3O4

  • Chemical Name:

    Ranirestat

  • Synonyms:

    Spiro[pyrrolidine-3,4′(1′H)-pyrrolo[1,2-a]pyrazine]-1′,2,3′,5(2′H)-tetrone,2′-[(4-bromo-2-fluorophenyl)methyl]-,(3R)-;Spiro[pyrrolidine-3,4′(1′H)-pyrrolo[1,2-a]pyrazine]-1′,2,3′,5(2′H)-tetrone,2′-[(4-bromo-2-fluorophenyl)methyl]-,(-)-;Spiro[pyrrolidine-3,4′(1′H)-pyrrolo[1,2-a]pyrazine]-1′,2,3′,5(2′H)-tetrone,2′-[(4-bromo-2-fluorophenyl)methyl]-,(3′R)-;(3R)-2′-[(4-Bromo-2-fluorophenyl)methyl]spiro[pyrrolidine-3,4′(1′H)-pyrrolo[1,2-a]pyrazine]-1′,2,3′,5(2′H)-tetrone;AS 3201;Ranirestat;(3R)-2′-(4-Bromo-2-fluorobenzyl)-1′,2′,3′,4′-tetrahydrospiro[pyrrolidine-3,4′-pyrrolo[1,2-a]pyrazine]-1′,2,3′,5-tetraone;(3R)-2′-(4-Bromo-2-fluorobenzyl)spiro[pyrrolidine-3,4′-1′H-pyrrolo[1,2-a]pyrazine]-1′,2,3′,5(2′H)-tetraone

Description

Ranirestat is a structurally novel and stereospecifically potent aldose reductase (AKR1B; EC 1.1.1.21) inhibitor, which contains a succinimide ring that undergoes ring-opening at physiological pH levels. It has been used in trials studying the treatment of Mild to Moderate Diabetic Sensorimotor Polyneuropathy.

Ranirestat Basic Attributes

420.18900

420.19

Z26P56GFTV

DTXSID80163642

Characteristics

91.97000

1.52790

1.83g/cm3

192-193 °C

702.7ºC at 760mmHg

378.8ºC

1.749

1.36E-19mmHg at 25°C

Safety Information

P280; P304 + P340 + P312; P305 + P351 + P338; P337 + P313

H315; H319; H335

Drug Information

Investigated for use/treatment in neuropathy (diabetic).

Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)

Ranirestat alleviates diabetic neuropathy, a complication of diabetes, by inhibiting aldose reductase and thereby inhibiting the accumulation of intracellular sorbitol that causes diabetic neuropathy. This drug has a stronger inhibitory effect and is longer acting compared to other drugs in this therapeutic area. Ranirestat showed good penetration into the nerve tissue, resulting in dose-dependent inhibition of intraneural accumulation of sorbitol and fructose in a clinical study.

2-(4-bromo-2-fluorobenzyl)-1,2,3,4-tetrahydropyrrolo(1,2-a)pyrazine-4-spiro-3'-pyrrolidine-1.2',3,5'-tetrone

Computed Properties

Molecular Weight:420.2
XLogP3:1.3
Hydrogen Bond Donor Count:1
Hydrogen Bond Acceptor Count:5
Rotatable Bond Count:2
Exact Mass:418.99170
Monoisotopic Mass:418.99170
Topological Polar Surface Area:88.5
Heavy Atom Count:26
Complexity:689
Defined Atom Stereocenter Count:1
Covalently-Bonded Unit Count:1
Compound Is Canonicalized:Yes

Scan the QR Code to Share

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.